Chesterfield, MO, United States of America

Daniel P Getman

This inventor holds 170 USPTO granted patents, plus 2 CIPO patents, primarily in Retroviral Protease Inhibitors (CPC class C07D-). Top assignees: G.d. Searle & Company, Monsanto Company, G.d. Searle LLC. Active years: 1986-2012.

USPTO Granted Patents = 170

% Patents Active = 71.8

CIPO Patents = 2 (Patent Applications = 16)

Average Co-Inventor Count = 5.5

ph-index = 17

Forward Citations = 1,186(Granted Patents)

Forward Citations (Not Self Cited) = 741(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

St. Louis, MO (US) (1986 - 1994)
Chestertfield, MO (US) (1999 - 2001)
Chesterfild, MO (US) (2004)
Chesterfield, MO (US) (1995 - 2012)

Company Filing History:

107 out of 1,323

G.d. Searle & Company

Pharmacia Corporation

patents

5. 1 out of 202

Elan Pharmaceuticals, Inc.

Monsanto Company of St. Louis

Pharmacia & Upjohn Company

patents

10. 1 out of 1

Pharmacia Corporation (Monsanto Corporation)

patent

11. 5 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1986-2012

Loading Chart...

Areas of Expertise:

Hydroxyethylamines

Amino Acid Derivatives

Retroviral Protease Inhibitors

Sulfonamides

Sulfamic Acid

Metalloprotease Inhibitors

Cyclic Sulfones

Heterocyclecarbonyl

Substituted Hydroxyethylamines

Bis-Sulfonamide

Succinoylamino

170 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE43802 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2012-11-12),

2. RE43596 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2012-08-20),

3. RE42889 - α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2011-10-31),

4. 7829564 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2010-11-09),

5. 7531538 - α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2009-05-12),

6. 7498436 - Substituted hydroxyethylamines (2009-03-03),

7. 7339078 - Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors (2008-03-04),

8. 7320983 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2008-01-22),

9. 7312333 - Retroviral protease inhibitors (2007-12-25),

10. 7297793 - Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors (2007-11-20),

11. 7232817 - α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2007-06-19),

12. 7202258 - α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors (2007-04-10),

13. 7199158 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2007-04-03),

14. 7189864 - Method of preparing intermediates useful in synthesis of retroviral protease inhibitors (2007-03-13),

15. 7161033 - Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors (2007-01-09),

Title: Daniel P Getman: A Pioneer in Retroviral Protease Inhibitors

Introduction:

Daniel P Getman, based in Chesterfield, MO (US), is a renowned inventor and scientist who has made significant contributions to the field of retroviral protease inhibitors. With an impressive collection of 146 patents to his name, Getman's groundbreaking work revolves around the development of α- and β-amino acid hydroxyethylamino sulfonamides as effective inhibitors of HIV protease.

Latest Patents:

Among his latest patents, Getman has successfully introduced the α- and β-amino acid hydroxyethylamino sulfonamides as potent retroviral protease inhibitors. These compounds display exceptional efficacy in inhibiting HIV protease activity, offering potential advancements in the treatment of HIV and related retroviral infections.

Career Highlights:

Throughout his career, Daniel P Getman has contributed his expertise to notable companies such as G.D. Searle & Company and Monsanto Corporation. His work has paved the way for groundbreaking advancements in the pharmaceutical industry, specifically in the area of retroviral protease inhibitors.

Collaborations:

Getman's innovative contributions have been supported by a network of talented colleagues. Two notable collaborators include Gary A DeCrescenzo and Michael L Vazquez. Their collaborations have led to the successful development and optimization of retroviral protease inhibitors, strengthening the field's ability to combat HIV and other retroviral infections.

Conclusion:

Daniel P Getman's prolific career as an inventor and scientist has revolutionized the field of retroviral protease inhibitors. Through his expertise and numerous patents, he has expanded our understanding of HIV treatment possibilities. Getman's contributions, alongside his collaborative efforts, continue to drive advancements in the fight against retroviral infections.